PNPedro Oliva Nacarino

Pedro Oliva Nacarino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pedro Oliva Nacarino has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Latent orbital pseudotumor secondary to systemic lupus erythematosus

    by María Rico, José Bernardino Díaz‐López, Jorge Peña, Pedro Oliva‐Nacarino

    Key Clinical Message: Orbital inflammatory pseudotumor is a rare complication of systemic lupus erythematosus. It may present a challenge for differential diagnosis, especially in the context of treatment with hydroxychloroquine, although dosage and duration of the treatment may guide us. Although high antibody titers can be found, this is not specific.


  • Increased natural killer cell chemotaxis to CXCL12 in patients with multiple sclerosis

    by Esther Serrano-Pertierra, Miguel A. Blanco-Gelaz, Pedro Oliva-Nacarino, Pablo Martínez-Camblor, Javier Villafani, Carlos López-Larrea, Eva Cernuda-Morollón


  • Open Access

    Microparticles in multiple sclerosis and clinically isolated syndrome: effect on endothelial barrier function

    by Beatriz Marcos-Ramiro, Pedro Oliva Nacarino, Esther Serrano-Pertierra, Miguel Ángel Blanco-Gelaz, Babette B Weksler, Ignacio A Romero, Pierre O Couraud, Alberto Tuñón, Carlos López-Larrea, Jaime Millán, et al.

    Cell-derived microparticles are secreted in response to cell damage or dysfunction. Endothelial and platelet dysfunction are thought to contribute to the development of multiple sclerosis (MS). Our aim here is, first, to compare the presence of microparticles of endothelial and platelet origin in plasma from patients with different clinical forms of MS and with clinically isolated syndrome. Second, to investigate the effect of microparticles on endothelial barrier function. Platelet-poor plasma from 95 patients (12 with clinically isolated syndrome, 51 relapsing-remitting, 23 secondary progressive, 9 primary progressive) and 49 healthy controls were analyzed for the presence of platelet-derived and endothelium-derived microparticles by flow cytometry. The plasma concentration of platelet-derived and endothelium-derived microparticles increased in all clinical forms of MS and in clinically isolated syndrome versus controls. The response of endothelial barriers to purified microparticles was measured by electric cell-substrate impedance sensing. Microparticles from relapsing-remitting MS patients induced, at equivalent concentrations, a stronger disruption of endothelial barriers than those from healthy donors or from patients with clinically isolated syndrome. MS microparticles acted synergistically with the inflammatory mediator thrombin to disrupt the endothelial barrier function. Plasma microparticles should be considered not only as markers of early stages of MS, but also as pathological factors with the potential to increase endothelial permeability and leukocyte infiltration.